Pacific Biosciences Of California (PACB) Share-based Compensation (2010 - 2026)

Pacific Biosciences Of California's Share-based Compensation history runs 17 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 84.92% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 79.59% decrease from a year earlier, with the FY2025 full-year figure at $41.7 million, down 41.34% from the prior year.
• Share-based Compensation declined to $4.5 million in Q1 2026 per PACB's latest filing, from $9.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $71.0 million in Q4 2024 and bottomed at -$36.7 million in Q3 2024.
• The 5-year median for Share-based Compensation is $17.2 million (2024), against an average of $13.8 million.
• Across the five-year window, Share-based Compensation soared 2009.79% in 2023 and sank 286.6% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $18.0 million in 2022, then slipped by 7.64% to $16.6 million in 2023, then soared by 328.34% to $71.0 million in 2024, then sank by 86.5% to $9.6 million in 2025, then plunged by 53.49% to $4.5 million in 2026.
• Per Business Quant, the three latest PACB Share-based Compensation figures stand at $4.5 million (Q1 2026), $9.6 million (Q4 2025), and $11.0 million (Q3 2025).